Compare BLNK & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | CALC |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 88.3M |
| IPO Year | 2008 | 2020 |
| Metric | BLNK | CALC |
|---|---|---|
| Price | $0.58 | $0.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $1.95 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 459.7K |
| Earning Date | 05-11-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $0.46 |
| 52 Week High | $2.65 | $7.20 |
| Indicator | BLNK | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 33.10 |
| Support Level | N/A | $0.49 |
| Resistance Level | $0.72 | $0.79 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 28.00 | 25.83 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.